This poster reviews the CATALYST trial, which aims to understand what fraction of patients with difficult-to-control diabetes have hypercortisolism and whether treatment of hypercortisolism in these patients is safe and leads to improvements in glycemic control. More than 1000 patients were screened, and 24% of them had hypercortisolism. We also identified clinical characteristics, such as age, ethnicity, and number of medications a patient is taking, that make it more likely that a patient with difficult-to-control diabetes has hypercortisolism. The Part 2 treatment phase of CATALYST is still ongoing.
